The recent phase III BETonMACE trial, designed to investigate the impact of APA on cardiovascular outcomes in 2,425 patients with diabetes after an acute coronary syndrome, failed to meet the primary endpoint (cardiovascular death, non-fatal myocardial infarction, or stroke), but showed a favorable trend (18% difference in relative risk), indicating that APA might be a promising treatment option and suggesting that larger clinical trials are needed in this patient population.
1
—
—